This would be my first funding target if I had the money.

Beyond science, Brooke sees three main hurdles: regulation, manufacturing and physician usability. Public acceptance, he says, already appears strong. Regulatory pathways may be comparatively favorable, given the long histories of the cocktail’s components and existing approvals for immune deficiency states. Manufacturing is always a challenge for biologics at scale, but protein production is mature and scalable, and the company is building internal capacity.

The immediate obstacle, Brooke argues, is complexity. Intervene Immune is developing a dosing system designed to be relatively foolproof for doctors, and expects to build an AI assistant to support implementation as sufficient data accumulates.

Intervene Immune’s closing sentiment is less biotech slogan and more biological provocation. “No matter how old you may be, your body still remembers how to be young,” Brooke says.